Author:
Kobayashi Masahisa,Ohashi Toya,Kaneshiro Eiko,Higuchi Takashi,Ida Hiroyuki
Funder
T. Ohashi has active research support from Sanofi Genzyme Corporation, Dainippon Sumitomo Pharma and AVROBIO Inc.
H. Ida has active research support from Sanofi Genzyme Corporation and Dainippon Sumitomo Pharma.
Publisher
Springer Science and Business Media LLC
Subject
Genetics(clinical),Genetics
Reference17 articles.
1. Germain DP. Fabry disease. Orphanet J Rare Dis. 1010;5:30.
2. Germain DP, Fan JQ. Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: in vitro and preclinical studies. Int. J Clin Pharmacol Ther.. 2009;47 Suppl 1:S111–117.
3. Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, et al. Treatment of Fabry disease with the pharmacological chaperone migalastat. N Engl J Med. 2016;375:545–55.
4. Hughes DA, Nicholls K, Shankar SP, Sunder-Plassmann G, Koeller D, Nedd K, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomized phase III ATTRACT study. J Med Genet. 2017;54:288–96.
5. Benjamin ER, Della Valle MC, Wu X, Katz E, Pruthi F, Bond S, et al. The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Genet Med. 2017;19:430–8.
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献